CRDL
Cardiol Therapeutics Inc. NASDAQ Listed Jan 15, 2019$1.04
+0.00%
vs $1.04
Mkt Cap $90.5M
52w Low $0.93
16.2% of range
52w High $1.63
50d MA $1.25
200d MA $1.11
P/E (TTM)
—
EV/EBITDA
—
P/B
5.1x
Debt/Equity
0.0x
ROE
—
P/FCF
-3.8x
RSI (14)
31.60
ATR (14)
$0.05
Beta
0.43
50d MA
$1.25
200d MA
$1.11
Avg Volume
362.9K
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
2265 Upper Middle Road East · Oakville, ON L6H 0G5 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.09 | -0.05 | +43.3% | 1.22 | +2.5% | +10.7% | +3.7% | +0.7% | -1.4% | +0.7% | — |
| Nov 13, 2025 | AMC | -0.09 | -0.09 | +0.0% | 1.02 | +3.9% | +0.0% | -3.9% | +5.1% | -3.3% | -3.2% | — |
| Aug 14, 2025 | AMC | -0.11 | -0.07 | +36.4% | 1.34 | +1.5% | -2.2% | -6.9% | -6.6% | +1.8% | +0.9% | — |
| May 13, 2025 | AMC | -0.13 | -0.10 | +23.1% | 1.15 | +0.0% | -3.5% | +2.7% | -2.6% | +0.9% | +0.0% | — |
| Mar 31, 2025 | AMC | -0.08 | -0.07 | +12.5% | 0.97 | -1.0% | -4.4% | -0.6% | -1.3% | -11.0% | +4.9% | — |
| Nov 14, 2024 | AMC | -0.10 | -0.13 | -30.0% | 1.86 | -1.1% | -2.2% | -1.6% | -7.8% | -5.5% | +1.3% | — |
| Aug 12, 2024 | AMC | -0.10 | -0.07 | +30.0% | 2.00 | +3.0% | +5.0% | -5.2% | +2.5% | -1.5% | -3.0% | — |
| May 14, 2024 | AMC | -0.06 | -0.10 | -66.7% | 2.18 | +4.1% | +6.4% | +1.7% | -8.1% | +0.5% | +1.8% | — |
| Mar 26, 2024 | AMC | -0.09 | -0.09 | +0.0% | 1.82 | +2.7% | -1.1% | +0.6% | +6.1% | -5.7% | +1.7% | — |
| Nov 14, 2023 | AMC | -0.12 | -0.07 | +41.7% | 0.86 | -2.1% | -2.8% | +0.6% | -0.4% | +2.3% | -2.4% | — |
| Aug 10, 2023 | AMC | -0.12 | -0.09 | +25.0% | 0.95 | +1.1% | -3.2% | +1.4% | +1.3% | -2.2% | -1.5% | — |
| May 15, 2023 | AMC | -0.15 | -0.08 | +46.7% | 0.55 | +0.0% | +9.7% | +5.1% | -7.4% | +0.5% | +11.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.41 | $1.42 | +0.7% | -1.4% | +0.7% | -7.9% | +7.0% | +0.0% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.04 | -1.9% | +1.9% | -1.9% | -3.8% | +2.0% | +0.0% |
| Dec 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.05 | $1.10 | +4.8% | -9.5% | -2.2% | +1.6% | +1.8% | +9.2% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.06 | +0.0% | -4.7% | +0.0% | -4.0% | +2.5% | +8.6% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.81 | $0.78 | -3.7% | +4.9% | -3.5% | +11.6% | -2.1% | +6.8% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.20 | $1.21 | +0.8% | -2.5% | -5.1% | +6.3% | +0.0% | -2.5% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.37 | $1.37 | +0.0% | -2.2% | -2.2% | -2.3% | -2.3% | +0.8% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $1.62 | -1.8% | -5.5% | +1.3% | +2.5% | -4.9% | -0.6% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.85 | $1.87 | +1.1% | +1.6% | +2.1% | -3.6% | -1.1% | -0.5% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.36 | $2.56 | +8.5% | +2.1% | -8.7% | -5.5% | -9.1% | -2.1% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.49 | $2.53 | +1.6% | -3.2% | +18.7% | +0.0% | +3.8% | -20.5% |
| May 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.18 | $2.29 | +5.0% | +2.3% | +5.4% | +0.0% | +2.1% | +7.1% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.18 | $2.24 | +2.8% | +0.0% | +6.4% | +1.7% | -8.1% | +0.5% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Tejara Capital Ltd | 5,130,122 | $7M | — | Mar 2026 |
| 2 | Citadel Advisors Llc | 819,904 | $1M | New | Mar 2026 |
| 3 | Two Sigma Investments, Lp | 534,211 | $721K | Added | Mar 2026 |
| 4 | Morgan Stanley | 688,926 | $657K | Added | Dec 2025 |
| 5 | Renaissance Technologies Llc | 229,806 | $310K | New | Mar 2026 |
| 6 | 1832 Asset Management L.p. | 100,000 | $135K | — | Mar 2026 |
| 7 | Mgo One Seven Llc | 100,000 | $135K | — | Mar 2026 |
| 8 | Susquehanna International Group, Llp | 70,396 | $95K | Reduced | Mar 2026 |
| 9 | Quadrature Capital Ltd | 47,887 | $65K | New | Mar 2026 |
| 10 | Jpmorgan Chase & Co | 48,077 | $59K | New | Mar 2026 |
| 11 | Marble Harbor Investment Counsel, Llc | 39,900 | $54K | — | Mar 2026 |
| 12 | Kovack Advisors, Inc. | 30,000 | $42K | New | Mar 2026 |
| 13 | Jane Street Group, Llc | 39,828 | $38K | Reduced | Dec 2025 |
| 14 | Boyer Financial Services, Inc. | 23,100 | $31K | Reduced | Mar 2026 |
| 15 | Royal Bank Of Canada | 21,648 | $29K | Added | Mar 2026 |
| 16 | Wealthspire Advisors, Llc | 15,151 | $20K | — | Mar 2026 |
| 17 | Eaton Financial Holdings Company, Llc | 14,000 | $19K | New | Mar 2026 |
| 18 | Wealth Enhancement Advisory Services, Llc | 16,552 | $17K | Reduced | Dec 2025 |
| 19 | Impact Partnership Wealth, Llc | 10,850 | $15K | — | Mar 2026 |
| 20 | Moneco Advisors, Llc | 15,000 | $14K | — | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 1
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Nasdaq Composite Index Fund | 52,435 | $53K | Feb 2026 |
Valuation
Market Cap
$90.5M
Enterprise Value
$69.1M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.14x
P/B
5.06x
P/S
—
P/FCF
-3.79x
EV/EBITDA
—
Shares Out
87.0M
Financials (TTM)
Revenue
$0
Net Income
-$36.4M
EBITDA
-$36.3M
Free Cash Flow
-$23.9M
Op Cash Flow
-$23.9M
EPS Basic
$-0.39
EPS Diluted
$-0.39
EPS Forward
$-0.53
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$23.6M
Total Liab.
$5.7M
Total Equity
$17.9M
Cash
$21.4M
LT Debt
$0
Book Value/Sh
$0.21
Debt/Equity
0.01x
Current Ratio
4.16
Quick Ratio
4.16
Returns & Growth
ROE
—
ROA
—
ROIC
-190.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
+23.5%
Price Returns
2W
-10.9%
1M
-11.6%
3M
+19.6%
6M
+16.2%
12M
-2.4%
Technicals
52W High
$1.63
52W Low
$0.93
50d MA
$1.25
200d MA
$1.11
RSI (14)
31.60
ATR (14)
$0.05
Beta
0.43
Avg Volume
363K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$8.00
High
$8.00
Low
$8.00
Median
$8.00
Data updated apr 25, 2026 3:08am
· Source: financialmodelingprep.com